EyePoint Pharmaceuticals (EYPT) Tops Q3 EPS by 14c

EyePoint Pharmaceuticals (NASDAQ: EYPT) reported Q3 EPS of ($0.49), $0.14 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $10.01 million versus the consensus estimate of $11.61 million.

For earnings history and earnings-related data on EyePoint Pharmaceuticals (EYPT) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• S&P 500 above 8,000 in 2026 now looks ambitious, Citi says
• KeyBanc Starts Oiln (OLN) at Overweight